Author

Paul Pollack

MIRIKIZUMAB REDUCES ABDOMINAL PAIN IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE
MIRIKIZUMAB REDUCES ABDOMINAL PAIN IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE

Paul Pollack  et al.

ASSOCIATION OF HISTOLOGIC MEASUREMENT WITH ENDOSCOPIC OUTCOMES AFTER ONE YEAR OF TREATMENT WITH MIRIKIZUMAB IN PATIENTS WITH MODERATE TO SEVERE CROHN’S DISEASE
ASSOCIATION OF HISTOLOGIC MEASUREMENT WITH ENDOSCOPIC OUTCOMES AFTER ONE YEAR OF TREATMENT WITH MIRIKIZUMAB IN PATIENTS WITH MODERATE TO SEVERE CROHN’S DISEASE

Paul Pollack  et al.

HISTOLOGIC DISEASE ACTIVITY CORRELATES WITH ENDOSCOPIC SEVERITY IN PATIENTS WITH MODERATE TO SEVERE CROHN’S DISEASE
HISTOLOGIC DISEASE ACTIVITY CORRELATES WITH ENDOSCOPIC SEVERITY IN PATIENTS WITH MODERATE TO SEVERE CROHN’S DISEASE

Paul Pollack  et al.

MIRIKIZUMAB THERAPY IS ASSOCIATED WITH IMPROVED FATIGUE IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE
MIRIKIZUMAB THERAPY IS ASSOCIATED WITH IMPROVED FATIGUE IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE

Paul Pollack  et al.

IMPACT OF MIRIKIZUMAB THERAPY ON HISTOLOGIC MEASURES OF INTESTINAL INFLAMMATION IN A PHASE 2 STUDY OF PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE
IMPACT OF MIRIKIZUMAB THERAPY ON HISTOLOGIC MEASURES OF INTESTINAL INFLAMMATION IN A PHASE 2 STUDY OF PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE

Paul Pollack  et al.

IMPROVEMENT IN FATIGUE WITH MIRIKIZUMAB THERAPY IS ASSOCIATED WITH CLINICAL REMISSION AND PAIN IMPROVEMENTS BUT NOT WITH ENDOSCOPIC RESPONSE IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE
IMPROVEMENT IN FATIGUE WITH MIRIKIZUMAB THERAPY IS ASSOCIATED WITH CLINICAL REMISSION AND PAIN IMPROVEMENTS BUT NOT WITH ENDOSCOPIC RESPONSE IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE

Paul Pollack  et al.

IMPROVEMENT IN FATIGUE WITH MIRIKIZUMAB THERAPY IS ASSOCIATED WITH IMPROVEMENTS IN PATIENT-REPORTED OUTCOMES IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE
IMPROVEMENT IN FATIGUE WITH MIRIKIZUMAB THERAPY IS ASSOCIATED WITH IMPROVEMENTS IN PATIENT-REPORTED OUTCOMES IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE

Paul Pollack  et al.

EFFECT OF MIRIKIZUMAB ON INFLAMMATORY BIOMARKERS IN A PHASE 2 STUDY OF PATIENTS WITH CROHN'S DISEASE
EFFECT OF MIRIKIZUMAB ON INFLAMMATORY BIOMARKERS IN A PHASE 2 STUDY OF PATIENTS WITH CROHN'S DISEASE

Paul Pollack  et al.

EVALUATION OF SYMPTOM IMPROVEMENT DURING INDUCTION IN PATIENTS WITH CROHN'S DISEASE TREATED WITH MIRIKIZUMAB
EVALUATION OF SYMPTOM IMPROVEMENT DURING INDUCTION IN PATIENTS WITH CROHN'S DISEASE TREATED WITH MIRIKIZUMAB

Paul Pollack  et al.

EFFECT OF 52 WEEKS OF MIRIKIZUMAB ON INFLAMMATORY BOWEL DISEASE QUESTIONNAIRE SCORES IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE
EFFECT OF 52 WEEKS OF MIRIKIZUMAB ON INFLAMMATORY BOWEL DISEASE QUESTIONNAIRE SCORES IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE

Paul Pollack  et al.

EFFICACY AND SAFETY OF MIRIKIZUMAB AFTER 52-WEEKS MAINTENANCE TREATMENT IN PATIENTS WITH MODERATE-TO-SEVERE CROHN'S DISEASE
EFFICACY AND SAFETY OF MIRIKIZUMAB AFTER 52-WEEKS MAINTENANCE TREATMENT IN PATIENTS WITH MODERATE-TO-SEVERE CROHN'S DISEASE

Paul Pollack  et al.

Item 1 - 11 / 11
1